Clozapine remains the antipsychotic agent of choice for treatment-resistant schizophrenia; however, its efficacy is frequently hampered by adverse effects such as hypersalivation and sialorrhea. These ...

Clozapine remains the antipsychotic agent of choice for treatment‐resistant schizophrenia; however, its efficacy is frequently hampered by adverse effects such as hypersalivation and sialorrhea. These ...

Multiple psychiatric groups have asked the US Food and Drug Administration (FDA) to consider holding a public meeting about its approach to risk management of the schizophrenia drug clozapine, which ...

Even when effectively treated, schizophrenia can be devastating, impairing a person’s social and family life, ability to work, physical health, and quality of life. Those who have schizophrenia often ...

The FDA no longer expects prescribers, pharmacies, and patients to participate in the risk evaluation and mitigation strategy (REMS) program for the antipsychotic clozapine, the agency announced this ...

An inter-departmental research team has conducted an analytic real-world cohort study on the association of clozapine, a highly efficacious antipsychotic drug, with the incidence of blood cancer.

Researchers analysed and then meta-analysed data from two register-based, nationwide cohort studies in Finland (1996-2017) and Sweden (2006-2023) and included 23,206 patients with schizophrenia (mean ...

Federal regulators will no longer require patients to provide blood tests before receiving the drug from pharmacies. By Ellen Barry The Food and Drug Administration has taken a crucial step toward ...

An inter-departmental research team at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has conducted the world's first analytic real-world cohort study on the association of ...